Index RUT P/E - EPS (ttm) -3.64 Insider Own 41.12% Shs Outstand 49.82M Perf Week -1.79%
Market Cap 997.03M Forward P/E - EPS next Y -3.96 Insider Trans 10.30% Shs Float 36.97M Perf Month 73.74%
Income -177.81M PEG - EPS next Q -1.03 Inst Own 46.20% Short Float 6.00% Perf Quarter 23.39%
Sales 0.00M P/S - EPS this Y -6.33% Inst Trans 13.18% Short Ratio 2.54 Perf Half Y 32.44%
Book/sh 3.84 P/B 4.14 EPS next Y -1.88% ROA -77.72% Short Interest 2.22M Perf Year 24.26%
Cash/sh 3.16 P/C 5.03 EPS next 5Y -3.06% ROE -82.24% 52W Range 8.24 - 18.38 Perf YTD 29.00%
Dividend Est. - P/FCF - EPS past 5Y -170.42% ROI -92.97% 52W High -13.60% Beta -0.19
Dividend TTM - Quick Ratio 14.02 Sales past 5Y 0.00% Gross Margin - 52W Low 92.70% ATR (14) 1.35
Dividend Ex-Date - Current Ratio 14.02 EPS Y/Y TTM -106.10% Oper. Margin - RSI (14) 61.54 Volatility 8.95% 10.47%
Employees 51 Debt/Eq 0.00 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 38.29
Option/Short Yes / Yes LT Debt/Eq 0.00 EPS Q/Q -61.06% Payout - Rel Volume 2.47 Prev Close 14.66
Sales Surprise - EPS Surprise 9.01% Sales Q/Q - Earnings Feb 12 BMO Avg Volume 872.25K Price 15.88
SMA20 11.15% SMA50 36.85% SMA200 29.82% Trades
Volume 2,154,452 Change 8.32%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-10-24 Initiated H.C. Wainwright
Buy
$30
Apr-02-24 Initiated Goldman
Buy
$30
Mar-07-23 Initiated Wells Fargo
Overweight
$27
Mar-07-23 Initiated Stifel
Buy
$45
Mar-07-23 Initiated Guggenheim
Buy
$32
Mar-07-23 Initiated Evercore ISI
Outperform
Mar-07-23 Initiated Credit Suisse
Outperform
$40
Mar-07-23 Initiated BofA Securities
Buy
$39
Mar-29-25 02:30PM
Mar-25-25 11:28AM
08:00AM
Mar-18-25 07:58PM
(Insider Monkey) +8.51%
+8.55%
04:01PM
08:00AM
Loading…
Mar-17-25 08:00AM
Mar-11-25 10:20PM
Mar-10-25 04:01PM
01:50PM
12:57PM
07:00AM
06:30AM
Mar-07-25 04:01PM
Feb-13-25 02:19AM
(Thomson Reuters StreetEvents)
02:10AM
07:00AM
Loading…
Feb-12-25 07:00AM
Feb-05-25 04:05PM
Feb-04-25 08:00AM
Jan-09-25 08:29AM
Jan-08-25 08:00AM
Nov-12-24 11:00PM
(TipRanks) -10.32%
-6.95%
10:12AM
(Thomson Reuters StreetEvents)
Nov-11-24 04:05PM
Nov-05-24 04:05PM
Nov-04-24 04:05PM
Oct-30-24 08:00AM
Oct-22-24 08:00AM
Sep-25-24 08:00AM
Aug-28-24 08:00AM
Aug-13-24 04:05PM
04:05PM
Loading…
Aug-05-24 04:05PM
Jul-12-24 07:01PM
07:01PM
Jun-21-24 03:11AM
Jun-15-24 02:53AM
Jun-14-24 08:00AM
02:43AM
Jun-03-24 08:00AM
May-13-24 11:45AM
May-09-24 11:56AM
07:00AM
May-06-24 08:00AM
May-02-24 08:00AM
Apr-05-24 12:16AM
Mar-22-24 10:51AM
Mar-21-24 11:53AM
09:11AM
07:00AM
Mar-13-24 04:05PM
Feb-08-24 08:00AM
Jan-29-24 04:05PM
Jan-17-24 12:00PM
Jan-04-24 04:05PM
Dec-21-23 04:05PM
Nov-12-23 09:22AM
Nov-11-23 11:30AM
Nov-09-23 04:05PM
(GlobeNewswire) -9.31%
-12.84%
Nov-07-23 05:12PM
(GuruFocus.com) +8.02%
-6.74%
04:05PM
Nov-02-23 10:00AM
Oct-31-23 04:05PM
Oct-13-23 04:10PM
(GlobeNewswire) +5.59%
+5.19%
Sep-19-23 04:00PM
Sep-14-23 04:05PM
Sep-11-23 04:05PM
Sep-10-23 07:47AM
07:45AM
Sep-09-23 05:00AM
Sep-05-23 04:05PM
09:55AM
Aug-29-23 04:05PM
Aug-22-23 05:45PM
Aug-07-23 04:05PM
(GlobeNewswire) -6.02%
+6.96%
Jul-31-23 04:05PM
Jul-17-23 04:01PM
Jun-09-23 08:04AM
May-31-23 08:00AM
May-15-23 04:01PM
May-10-23 08:39AM
May-02-23 08:00AM
May-01-23 08:00AM
Apr-27-23 04:47PM
Mar-15-23 04:01PM
Mar-04-23 04:30PM
Mar-01-23 04:05PM
Feb-20-23 08:00AM
Feb-17-23 12:08PM
(American City Business Journals)
Feb-14-23 04:01PM
Feb-10-23 05:16PM
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Samsara BioCapital GP, LLC 10% Owner Mar 13 '25 Buy 13.50 600,000 8,100,000 5,674,916 Mar 17 09:05 PM AKKARAJU SRINIVAS Director Mar 13 '25 Buy 13.50 600,000 8,100,000 5,674,916 Mar 17 09:04 PM RA CAPITAL MANAGEMENT, L.P. Director Mar 13 '25 Buy 13.50 1,296,296 17,499,996 4,280,051 Mar 17 07:56 PM Rodman David Malcom Chief Medical Officer Mar 12 '25 Option Exercise 1.08 6,349 6,857 170,869 Mar 13 05:15 PM Rodman David Malcom Chief Medical Officer Feb 12 '25 Option Exercise 1.08 6,348 6,856 164,520 Feb 13 05:29 PM Levy Adam Scott CFO and Secretary Jan 13 '25 Sale 9.10 10,757 97,864 226,097 Jan 15 09:46 PM Rodman David Malcom Chief Medical Officer Jan 13 '25 Option Exercise 0.84 11,367 9,567 158,172 Jan 15 09:45 PM Congleton Jon Chief Executive Officer Jan 13 '25 Sale 9.06 18,333 166,082 877,608 Jan 15 09:44 PM Congleton Jon Officer Jan 13 '25 Proposed Sale 9.06 18,333 166,083 Jan 13 06:34 PM Levy Adam Scott Officer Jan 13 '25 Proposed Sale 9.10 10,757 97,864 Jan 13 06:21 PM Rodman David Malcom Chief Medical Officer Dec 11 '24 Option Exercise 0.54 5,017 2,709 146,008 Dec 13 04:37 PM Rodman David Malcom Chief Medical Officer Nov 11 '24 Option Exercise 0.81 10,043 8,137 146,017 Nov 12 05:25 PM Rodman David Malcom Chief Medical Officer Nov 11 '24 Sale 15.00 5,026 75,398 140,991 Nov 12 05:25 PM Rodman David Malcom Officer Nov 11 '24 Proposed Sale 15.00 5,026 75,398 Nov 12 10:40 AM Rodman David Malcom Chief Medical Officer Nov 06 '24 Option Exercise 1.08 25,482 27,521 161,456 Nov 08 04:21 PM Rodman David Malcom Chief Medical Officer Nov 06 '24 Sale 15.03 25,482 383,066 135,974 Nov 08 04:21 PM Rodman David Malcom Officer Nov 06 '24 Proposed Sale 15.03 25,482 383,067 Nov 06 06:43 PM Levy Adam Scott CFO and Secretary Oct 11 '24 Sale 13.57 10,757 146,004 236,854 Oct 15 04:22 PM Rodman David Malcom Chief Medical Officer Oct 14 '24 Option Exercise 1.08 5,352 5,780 135,974 Oct 15 04:22 PM Rodman David Malcom Chief Medical Officer Oct 11 '24 Option Exercise 0.54 5,017 2,709 130,622 Oct 15 04:22 PM Congleton Jon Chief Executive Officer Oct 11 '24 Sale 13.52 15,271 206,433 895,941 Oct 15 04:21 PM Congleton Jon Officer Oct 11 '24 Proposed Sale 13.52 15,271 206,434 Oct 11 04:54 PM Levy Adam Scott Officer Oct 11 '24 Proposed Sale 13.57 10,757 146,004 Oct 11 04:48 PM Rodman David Malcom Chief Medical Officer Sep 12 '24 Option Exercise 1.08 6,349 6,857 125,605 Sep 12 04:32 PM Rodman David Malcom Chief Medical Officer Sep 11 '24 Option Exercise 0.54 5,018 2,710 119,256 Sep 12 04:32 PM Rodman David Malcom Chief Medical Officer Aug 12 '24 Option Exercise 0.84 11,365 9,565 114,238 Aug 13 04:20 PM Slingsby Brian Taylor Director Jul 24 '24 Sale 13.05 550,000 7,177,500 8,644,579 Jul 26 09:45 PM Rodman David Malcom Chief Medical Officer Jul 16 '24 Option Exercise 1.08 525 567 103,398 Jul 18 06:34 PM Rodman David Malcom Chief Medical Officer Jul 16 '24 Sale 15.00 525 7,876 102,873 Jul 18 06:34 PM Rodman David Malcom Chief Medical Officer Jul 12 '24 Option Exercise 1.08 6,349 6,857 102,873 Jul 12 04:39 PM Rodman David Malcom Chief Medical Officer Jul 11 '24 Option Exercise 0.54 5,017 2,709 96,524 Jul 12 04:39 PM Levy Adam Scott CFO and Secretary Jul 11 '24 Sale 13.14 10,757 141,394 247,611 Jul 12 04:37 PM Congleton Jon Chief Executive Officer Jul 11 '24 Sale 13.34 15,746 210,075 911,212 Jul 12 04:36 PM Congleton Jon Chief Executive Officer Jun 17 '24 Sale 12.25 17,766 217,712 958,505 Jun 20 05:44 PM Congleton Jon Chief Executive Officer Jun 18 '24 Sale 11.99 16,607 199,073 941,898 Jun 20 05:44 PM Congleton Jon Chief Executive Officer Jun 20 '24 Sale 11.73 14,940 175,237 926,958 Jun 20 05:44 PM Congleton Jon Chief Executive Officer Jun 13 '24 Sale 12.74 39,961 509,027 992,500 Jun 14 06:15 PM Congleton Jon Chief Executive Officer Jun 12 '24 Sale 12.77 16,607 212,013 1,032,461 Jun 14 06:15 PM Congleton Jon Chief Executive Officer Jun 14 '24 Sale 12.52 16,229 203,163 976,271 Jun 14 06:15 PM Levy Adam Scott CFO and Secretary Jun 11 '24 Sale 12.94 96,815 1,252,718 255,462 Jun 13 05:33 PM Rodman David Malcom Chief Medical Officer Jun 12 '24 Option Exercise 1.08 6,349 6,857 89,729 Jun 13 05:32 PM Rodman David Malcom Chief Medical Officer Jun 11 '24 Option Exercise 0.54 5,017 2,709 83,380 Jun 13 05:32 PM Rodman David Malcom Chief Medical Officer May 13 '24 Option Exercise 0.84 11,366 9,566 78,363 May 15 04:43 PM Rodman David Malcom Chief Medical Officer May 09 '24 Option Exercise 1.08 100 108 67,097 May 10 04:17 PM Rodman David Malcom Chief Medical Officer May 09 '24 Sale 15.00 100 1,500 66,997 May 10 04:17 PM Rodman David Malcom Chief Medical Officer Apr 12 '24 Option Exercise 1.08 6,349 6,857 66,997 Apr 15 04:24 PM Rodman David Malcom Chief Medical Officer Apr 11 '24 Option Exercise 0.54 5,017 2,709 60,648 Apr 15 04:24 PM
Index RUT P/E - EPS (ttm) -4.60 Insider Own 17.51% Shs Outstand 14.85M Perf Week -16.12%
Market Cap 174.83M Forward P/E - EPS next Y -5.18 Insider Trans 4.63% Shs Float 12.31M Perf Month -33.80%
Income -75.14M PEG - EPS next Q -1.06 Inst Own 93.71% Short Float 17.71% Perf Quarter -51.41%
Sales 0.93M P/S 187.99 EPS this Y -7.96% Inst Trans 55.45% Short Ratio 9.43 Perf Half Y -70.11%
Book/sh 20.89 P/B 0.56 EPS next Y -12.04% ROA -26.88% Short Interest 2.18M Perf Year -76.23%
Cash/sh 20.92 P/C 0.56 EPS next 5Y -8.29% ROE -30.28% 52W Range 13.47 - 74.49 Perf YTD -48.78%
Dividend Est. - P/FCF - EPS past 5Y -10.74% ROI -23.50% 52W High -84.28% Beta 1.38
Dividend TTM - Quick Ratio 20.84 Sales past 5Y 0.00% Gross Margin -251.57% 52W Low -13.07% ATR (14) 1.54
Dividend Ex-Date - Current Ratio 20.84 EPS Y/Y TTM -140.77% Oper. Margin -8930.27% RSI (14) 30.03 Volatility 15.04% 8.85%
Employees 107 Debt/Eq 0.04 Sales Y/Y TTM - Profit Margin -8123.68% Recom 1.14 Target Price 50.20
Option/Short Yes / Yes LT Debt/Eq 0.03 EPS Q/Q -8.67% Payout - Rel Volume 2.94 Prev Close 14.52
Sales Surprise - EPS Surprise 11.42% Sales Q/Q - Earnings Mar 24 AMC Avg Volume 231.05K Price 11.71
SMA20 -26.06% SMA50 -30.06% SMA200 -62.98% Trades
Volume 678,564 Change -19.35%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-27-24 Initiated BMO Capital Markets
Outperform
$65
Jun-11-24 Initiated Robert W. Baird
Outperform
$54
Apr-29-24 Initiated Leerink Partners
Outperform
$46
Mar-21-24 Initiated William Blair
Outperform
$61
Jan-08-24 Initiated H.C. Wainwright
Buy
$45
Jan-05-24 Initiated Stifel
Buy
$31
Jan-04-24 Initiated TD Cowen
Outperform
Mar-24-25 04:10PM
Feb-24-25 07:30AM
Nov-18-24 05:25PM
(Business Wire) -42.58%
-13.07%
04:14PM
(Investor's Business Daily)
09:48AM
(Investor's Business Daily)
06:45AM
Loading…
06:45AM
Nov-12-24 04:10PM
(Investor's Business Daily) -44.08%
10:18AM
(Investor's Business Daily)
06:58AM
Nov-11-24 04:01PM
Nov-05-24 07:54AM
Nov-04-24 07:30AM
Oct-21-24 07:30AM
Aug-09-24 02:52PM
07:30AM
07:30AM
Loading…
Aug-07-24 07:30AM
Jul-02-24 07:30AM
Jul-01-24 07:30AM
Jun-19-24 09:23AM
Jun-18-24 09:26AM
Jun-05-24 07:30AM
Jun-03-24 07:30AM
May-10-24 01:54PM
07:30AM
May-07-24 06:19AM
Apr-22-24 04:36PM
Mar-20-24 05:31AM
Mar-18-24 04:14PM
Mar-04-24 07:30AM
Feb-29-24 07:30AM
07:00AM
Loading…
Jan-16-24 07:00AM
Jan-05-24 07:00AM
Dec-19-23 07:00AM
Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company was founded in May 2007 and is headquartered in New York, NY.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Cvijic Christine Mikail President and CFO Mar 13 '25 Sale 16.94 4,501 76,247 72,343 Mar 17 05:14 PM Samsara BioCapital GP, LLC 10% Owner Nov 26 '24 Buy 25.83 48,770 1,259,623 1,717,127 Nov 27 04:39 PM Cvijic Christine Mikail President and CFO Nov 22 '24 Buy 20.48 24,000 491,400 76,844 Nov 25 09:29 PM McMinn Rachel Chief Executive Officer Nov 22 '24 Buy 20.40 47,500 969,000 1,297,859 Nov 25 09:29 PM
Index RUT P/E - EPS (ttm) -3.76 Insider Own 35.28% Shs Outstand 46.04M Perf Week -3.10%
Market Cap 187.43M Forward P/E - EPS next Y -2.45 Insider Trans 0.00% Shs Float 29.80M Perf Month 8.24%
Income -167.50M PEG - EPS next Q -0.94 Inst Own 89.07% Short Float 11.92% Perf Quarter -72.67%
Sales 0.00M P/S - EPS this Y 77.53% Inst Trans 24.98% Short Ratio 3.27 Perf Half Y -77.99%
Book/sh 7.82 P/B 0.52 EPS next Y 33.97% ROA -38.64% Short Interest 3.55M Perf Year -81.84%
Cash/sh 7.38 P/C 0.55 EPS next 5Y 46.30% ROE -43.76% 52W Range 3.00 - 25.45 Perf YTD -71.78%
Dividend Est. - P/FCF - EPS past 5Y - ROI -43.06% 52W High -84.01% Beta 0.46
Dividend TTM - Quick Ratio 13.79 Sales past 5Y 0.00% Gross Margin - 52W Low 35.67% ATR (14) 0.31
Dividend Ex-Date - Current Ratio 13.79 EPS Y/Y TTM - Oper. Margin - RSI (14) 40.37 Volatility 3.84% 5.68%
Employees 167 Debt/Eq 0.08 Sales Y/Y TTM - Profit Margin - Recom 3.29 Target Price 9.94
Option/Short Yes / Yes LT Debt/Eq 0.08 EPS Q/Q -26.76% Payout - Rel Volume 0.45 Prev Close 4.18
Sales Surprise - EPS Surprise 20.62% Sales Q/Q - Earnings Nov 12 AMC Avg Volume 1.09M Price 4.07
SMA20 0.25% SMA50 -24.04% SMA200 -71.91% Trades
Volume 494,558 Change -2.63%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-30-25 Downgrade William Blair
Outperform → Mkt Perform
Jan-30-25 Downgrade Truist
Buy → Hold
$32 → $7
Jan-30-25 Downgrade Piper Sandler
Overweight → Neutral
$34 → $4
Jan-30-25 Downgrade JP Morgan
Overweight → Underweight
Jan-30-25 Downgrade Jefferies
Buy → Hold
$32 → $3
Jan-30-25 Downgrade H.C. Wainwright
Buy → Neutral
Jan-30-25 Downgrade Chardan Capital Markets
Buy → Neutral
Nov-26-24 Initiated William Blair
Outperform
Jul-22-24 Initiated H.C. Wainwright
Buy
$33
Jul-08-24 Initiated Chardan Capital Markets
Buy
$28
Jun-27-24 Initiated Piper Sandler
Overweight
$37
Dec-05-23 Initiated Truist
Buy
$34
Dec-05-23 Initiated TD Cowen
Outperform
Dec-05-23 Initiated JP Morgan
Overweight
$23
Dec-05-23 Initiated Jefferies
Buy
$28
Show Previous Ratings
Mar-30-25 03:50AM
Mar-19-25 09:49AM
06:21AM
Mar-18-25 04:05PM
Feb-20-25 09:35AM
09:55AM
Loading…
Feb-12-25 09:55AM
Feb-03-25 12:00PM
Jan-29-25 04:05PM
Jan-10-25 08:00AM
Dec-23-24 10:49AM
Dec-17-24 08:00AM
Dec-16-24 06:34PM
Dec-12-24 09:55AM
Nov-12-24 04:05PM
Nov-05-24 04:05PM
09:23AM
Loading…
09:23AM
Aug-16-24 08:53PM
06:50PM
Aug-12-24 04:05PM
Jul-10-24 08:00AM
Jun-04-24 04:05PM
01:56PM
May-30-24 06:00AM
May-28-24 08:05AM
08:00AM
May-22-24 12:00PM
09:55AM
May-14-24 09:54PM
04:05PM
Apr-15-24 04:05PM
10:53PM
Loading…
Mar-21-24 10:53PM
04:05PM
Feb-29-24 04:01PM
Jan-03-24 08:05AM
Dec-18-23 04:04PM
(Commercial Observer)
+13.88%
Dec-13-23 10:51PM
04:05PM
Dec-11-23 07:53PM
Cargo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cell therapies for cancer patients. It is involved in evaluating its lead program, CRG-022, an autologous CD22 chimeric antigen receptor T-cell therapy candidate, in a potentially pivotal Phase 2 clinical trial in patients with large B-cell lymphoma whose disease relapsed or was refractory to CD19 CAR T-cell therapy. The company was founded by Crystal Mackall, Nancy Goodman, Louai Labanieh, and Robbie Majzner in December 2019 and is headquartered in San Carlos, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Chapman Gina President & CEO Sep 18 '24 Option Exercise 5.03 7,166 36,045 111,071 Sep 20 05:24 PM Chapman Gina President & CEO Sep 19 '24 Option Exercise 5.03 2,975 14,964 106,880 Sep 20 05:24 PM Chapman Gina President & CEO Sep 18 '24 Sale 25.09 7,166 179,775 103,905 Sep 20 05:24 PM Chapman Gina President & CEO Sep 19 '24 Sale 25.03 2,975 74,457 103,905 Sep 20 05:24 PM Radhakrishnan Anup Chief Financial Officer Sep 18 '24 Option Exercise 5.03 1,600 8,048 8,046 Sep 20 05:23 PM Radhakrishnan Anup Chief Financial Officer Sep 18 '24 Sale 25.28 1,600 40,452 6,446 Sep 20 05:23 PM ANUP RADHAKRISHNAN Officer Sep 18 '24 Proposed Sale 23.33 14,000 326,620 Sep 18 04:38 PM GINA CHAPMAN Director Sep 18 '24 Proposed Sale 23.33 75,000 1,749,750 Sep 18 04:36 PM Samsara BioCapital GP, LLC 10% Owner May 30 '24 Buy 17.00 294,000 4,998,000 4,415,689 Jun 03 09:45 PM
Index RUT P/E - EPS (ttm) -2.57 Insider Own 23.24% Shs Outstand 93.82M Perf Week -4.91%
Market Cap 3.04B Forward P/E - EPS next Y -1.21 Insider Trans -15.12% Shs Float 72.67M Perf Month -17.18%
Income -246.29M PEG - EPS next Q -0.66 Inst Own 94.21% Short Float 22.20% Perf Quarter -29.70%
Sales 0.00M P/S - EPS this Y 5.17% Inst Trans 24.41% Short Ratio 16.68 Perf Half Y 271.68%
Book/sh 3.93 P/B 8.18 EPS next Y 48.50% ROA -62.67% Short Interest 16.13M Perf Year 108.09%
Cash/sh 4.62 P/C 6.96 EPS next 5Y - ROE -82.95% 52W Range 6.76 - 46.98 Perf YTD -25.61%
Dividend Est. - P/FCF - EPS past 5Y -5.90% ROI -57.55% 52W High -31.57% Beta 0.57
Dividend TTM - Quick Ratio 9.61 Sales past 5Y -5.25% Gross Margin - 52W Low 375.59% ATR (14) 1.85
Dividend Ex-Date - Current Ratio 9.61 EPS Y/Y TTM -22.34% Oper. Margin - RSI (14) 36.24 Volatility 5.51% 5.25%
Employees 196 Debt/Eq 0.18 Sales Y/Y TTM -100.00% Profit Margin - Recom 1.00 Target Price 50.50
Option/Short Yes / Yes LT Debt/Eq 0.16 EPS Q/Q -16.67% Payout - Rel Volume 1.75 Prev Close 32.84
Sales Surprise - EPS Surprise -3.13% Sales Q/Q - Earnings Feb 27 BMO Avg Volume 967.02K Price 32.15
SMA20 -6.38% SMA50 -14.58% SMA200 27.14% Trades
Volume 1,691,211 Change -2.10%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-26-24 Reiterated H.C. Wainwright
Buy
$40 → $50
Oct-07-24 Reiterated H.C. Wainwright
Buy
$30 → $35
Mar-28-24 Initiated Raymond James
Strong Buy
$30
Oct-25-23 Upgrade Jefferies
Hold → Buy
$20
Apr-03-23 Resumed Piper Sandler
Overweight
$26
Sep-19-22 Resumed H.C. Wainwright
Buy
$30
Jul-12-22 Initiated Truist
Buy
$20
Mar-23-22 Initiated H.C. Wainwright
Buy
$24
Dec-22-21 Downgrade Jefferies
Buy → Hold
$52 → $28
Nov-19-21 Initiated Piper Sandler
Overweight
$56
Apr-26-21 Resumed Credit Suisse
Outperform
$65
Jan-11-21 Initiated Credit Suisse
Outperform
$65
Jan-06-21 Initiated JP Morgan
Overweight
$59
Mar-12-20 Initiated Robert W. Baird
Outperform
$35
Show Previous Ratings
Mar-30-25 03:50AM
02:50AM
Mar-25-25 07:30AM
Mar-17-25 08:31AM
Mar-16-25 07:00PM
04:15PM
Loading…
Mar-14-25 04:15PM
Feb-27-25 11:16PM
(Thomson Reuters StreetEvents)
+7.95%
07:00AM
Feb-26-25 07:24AM
Feb-25-25 04:15PM
Feb-24-25 01:10PM
Feb-21-25 08:00AM
Feb-14-25 04:15PM
Feb-10-25 08:00AM
Jan-29-25 08:05AM
08:00AM
Loading…
08:00AM
Jan-17-25 04:15PM
Jan-13-25 06:48PM
Jan-08-25 04:00PM
Jan-02-25 08:00AM
Dec-13-24 04:15PM
Dec-04-24 12:36PM
Nov-25-24 11:51AM
06:13AM
Nov-15-24 04:15PM
Nov-13-24 02:08AM
Nov-12-24 07:00AM
Nov-11-24 07:07AM
Nov-04-24 08:00AM
Nov-01-24 08:00AM
04:00PM
Loading…
Oct-31-24 04:00PM
08:00AM
Oct-22-24 08:00AM
Oct-21-24 09:55AM
Oct-18-24 04:15PM
Oct-11-24 06:30PM
Oct-09-24 05:34PM
(GuruFocus.com) -5.83%
-5.87%
05:38AM
Oct-08-24 11:08PM
08:29AM
06:43AM
Oct-07-24 04:13PM
(Investor's Business Daily) +361.99%
04:09PM
03:23PM
(The Wall Street Journal)
11:05AM
11:05AM
09:41AM
(Investor's Business Daily)
07:00AM
Sep-27-24 06:13AM
Sep-13-24 04:15PM
Sep-10-24 08:00AM
Sep-05-24 12:02AM
Sep-04-24 08:00AM
Sep-02-24 05:22PM
Aug-29-24 08:00AM
Aug-16-24 04:15PM
Aug-15-24 04:32AM
Aug-09-24 05:05AM
(Thomson Reuters StreetEvents)
Aug-08-24 07:00AM
Jul-23-24 08:00AM
Jul-12-24 04:15PM
Jul-08-24 06:42PM
12:30PM
Jun-24-24 07:00AM
Jun-18-24 04:15PM
Jun-03-24 04:00PM
May-28-24 08:00AM
May-22-24 07:00AM
May-20-24 08:00AM
May-17-24 04:15PM
May-14-24 08:00AM
May-07-24 01:53PM
10:19AM
08:52AM
07:00AM
Apr-24-24 06:33AM
Apr-12-24 04:15PM
Mar-20-24 05:31AM
Mar-19-24 10:52PM
07:00AM
Mar-15-24 04:15PM
08:18AM
Feb-28-24 08:00AM
Feb-16-24 04:15PM
Feb-15-24 08:00AM
Feb-06-24 08:00AM
Jan-25-24 08:00AM
Jan-23-24 08:00AM
Jan-22-24 07:00AM
(The Wall Street Journal)
Jan-18-24 05:01PM
Jan-12-24 04:15PM
Jan-04-24 08:00AM
Jan-02-24 01:57PM
Dec-30-23 07:01PM
Dec-19-23 08:00AM
Dec-15-23 04:15PM
Dec-10-23 09:05AM
Nov-17-23 04:15PM
Nov-12-23 12:32PM
Nov-07-23 08:14AM
Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Sacco Tracey Chief Commercial Officer Mar 24 '25 Option Exercise 10.00 5,000 50,000 78,250 Mar 25 07:39 PM Sacco Tracey Chief Commercial Officer Mar 24 '25 Sale 33.08 6,500 215,014 71,750 Mar 25 07:39 PM Moore Erin Interim PFO and PAO Mar 24 '25 Option Exercise 17.33 13,564 235,085 96,173 Mar 25 07:37 PM Moore Erin Interim PFO and PAO Mar 24 '25 Sale 33.12 13,564 449,237 82,609 Mar 25 07:37 PM Tracey Sacco Affiliate Mar 24 '25 Proposed Sale 33.00 41,500 1,369,500 Mar 24 07:20 PM Peng Katie Director Mar 17 '25 Sale 34.42 1,006 34,627 30,319 Mar 19 05:00 PM Katie Peng Director Mar 17 '25 Proposed Sale 34.60 4,037 139,680 Mar 17 06:50 PM Myles Edward H COO & CFO Mar 10 '25 Option Exercise 13.60 112,897 1,535,083 253,637 Mar 12 07:06 PM Myles Edward H COO & CFO Mar 10 '25 Sale 35.62 142,292 5,068,974 111,345 Mar 12 07:06 PM Edward Myles Officer Mar 10 '25 Proposed Sale 35.00 161,890 5,666,150 Mar 10 04:15 PM Qatanani Mo CHIEF SCIENTIFIC OFFICER Feb 19 '25 Option Exercise 10.19 48,308 492,186 179,594 Feb 20 07:55 PM Qatanani Mo CHIEF SCIENTIFIC OFFICER Feb 19 '25 Sale 37.40 68,510 2,562,479 111,084 Feb 20 07:55 PM Qatanani Mo CHIEF SCIENTIFIC OFFICER Feb 18 '25 Sale 36.83 4,135 152,288 131,286 Feb 20 07:55 PM Parlavecchio Caryn CHRO Feb 18 '25 Sale 36.83 5,296 195,046 140,258 Feb 20 06:30 PM Myles Edward H COO & CFO Feb 18 '25 Sale 36.83 7,809 287,598 140,740 Feb 20 06:18 PM Ho Junlin GENERAL COUNSEL Feb 18 '25 Sale 36.83 5,742 211,472 189,295 Feb 20 05:53 PM Backstrom Jay T. CHIEF EXECUTIVE OFFICER Feb 18 '25 Sale 36.83 18,372 676,622 311,991 Feb 20 05:41 PM Mohammed Qatanani Officer Feb 19 '25 Proposed Sale 36.95 68,510 2,531,444 Feb 19 04:15 PM Backstrom Jay T. CHIEF EXECUTIVE OFFICER Jan 16 '25 Sale 44.20 22,308 985,951 330,363 Jan 21 04:35 PM Marantz Jing L. CHIEF MEDICAL OFFICER Jan 16 '25 Sale 44.20 5,655 249,935 67,200 Jan 21 04:35 PM Sacco Tracey Chief Commercial Officer Jan 16 '25 Sale 44.20 3,890 171,927 45,395 Jan 21 04:35 PM Qatanani Mo CHIEF SCIENTIFIC OFFICER Jan 16 '25 Sale 44.20 7,347 324,717 135,421 Jan 21 04:35 PM Parlavecchio Caryn CHRO Jan 16 '25 Sale 44.20 6,434 284,365 145,554 Jan 21 04:35 PM Myles Edward H COO & CFO Jan 16 '25 Sale 44.20 12,539 554,189 148,549 Jan 21 04:35 PM Ho Junlin GENERAL COUNSEL Jan 16 '25 Sale 44.20 9,039 399,498 195,037 Jan 21 04:35 PM Invus Public Equities, L.P. 10% Owner Dec 10 '24 Sale 41.65 1,600,000 66,640,000 9,250,005 Dec 12 04:39 PM Invus Public Equities, L.P. 10% Owner Nov 25 '24 Sale 38.49 409,433 15,757,639 10,850,005 Nov 27 04:31 PM Marantz Jing L. CHIEF MEDICAL OFFICER Nov 25 '24 Option Exercise 8.59 6,375 54,761 79,230 Nov 26 05:00 PM Marantz Jing L. CHIEF MEDICAL OFFICER Nov 22 '24 Option Exercise 8.59 2,145 18,426 75,000 Nov 26 05:00 PM Marantz Jing L. CHIEF MEDICAL OFFICER Nov 25 '24 Sale 39.44 6,375 251,399 72,855 Nov 26 05:00 PM Marantz Jing L. CHIEF MEDICAL OFFICER Nov 22 '24 Sale 30.01 2,145 64,372 72,855 Nov 26 05:00 PM Marantz Jing L. CHIEF MEDICAL OFFICER Nov 11 '24 Option Exercise 8.59 2,105 18,082 74,960 Nov 13 04:40 PM Marantz Jing L. CHIEF MEDICAL OFFICER Nov 11 '24 Sale 30.00 2,105 63,158 72,855 Nov 13 04:40 PM Myles Edward H COO & CFO Oct 08 '24 Option Exercise 10.00 37,187 371,870 198,275 Oct 10 06:00 PM Myles Edward H COO & CFO Oct 08 '24 Sale 34.90 37,187 1,297,659 161,088 Oct 10 06:00 PM Myles Edward H COO & CFO Oct 07 '24 Sale 26.56 206,240 5,477,546 161,088 Oct 07 09:52 PM Sacco Tracey CHIEF COMMERCIAL OFFICER Oct 07 '24 Option Exercise 10.00 30,000 300,000 79,285 Oct 07 09:03 PM Sacco Tracey CHIEF COMMERCIAL OFFICER Oct 07 '24 Sale 25.62 30,000 768,677 49,285 Oct 07 09:03 PM AKKARAJU SRINIVAS Director Oct 07 '24 Sale 29.25 1,175,713 34,385,672 5,612,896 Oct 07 08:55 PM Marantz Jing L. CHIEF MEDICAL OFFICER Oct 07 '24 Option Exercise 8.59 109,375 939,531 182,230 Oct 07 08:51 PM Marantz Jing L. CHIEF MEDICAL OFFICER Oct 07 '24 Sale 27.21 109,375 2,976,468 72,855 Oct 07 08:51 PM AKKARAJU SRINIVAS Director Oct 07 '24 Proposed Sale 29.25 1,175,713 34,385,725 Oct 07 08:43 PM Tracey Sacco Officer Oct 07 '24 Proposed Sale 25.62 30,000 768,693 Oct 07 04:20 PM Jing Marantz Officer Oct 07 '24 Proposed Sale 32.50 120,000 3,900,000 Oct 07 04:18 PM Edward Myles Officer Oct 07 '24 Proposed Sale 32.50 243,427 7,911,378 Oct 07 04:16 PM Qatanani Mo CHIEF SCIENTIFIC OFFICER Sep 16 '24 Sale 8.58 1,936 16,611 142,768 Sep 19 08:15 AM Parlavecchio Caryn CHRO Aug 16 '24 Sale 9.33 1,451 13,538 151,988 Aug 19 05:00 PM Qatanani Mo CHIEF SCIENTIFIC OFFICER Jun 17 '24 Sale 8.98 2,315 20,800 144,704 Jun 18 05:56 PM Parlavecchio Caryn CHRO Jun 17 '24 Sale 8.98 4,305 38,680 153,439 Jun 18 05:55 PM Myles Edward H COO & CFO Jun 17 '24 Sale 8.98 9,458 84,978 201,518 Jun 18 05:54 PM Ho Junlin GENERAL COUNSEL Jun 17 '24 Sale 8.98 4,695 42,183 204,076 Jun 18 05:53 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
